Search

Displaying results 2261 - 2270 of 10000 in total
  1. Drug

    Paritaprevir

    go.drugbank.com/drugs/DB09297
    ApprovedInvestigational

    First approved in January 2015, Holkira Pak is indicated for the treatment of HCV genotype 1b with or without cirrhosis, and when combined with [DB00811] for the treatment of HCV genotype 1a with or without … First approved in December 2014, Viekira Pak is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with [DB00811] for the treatment of HCV

    Mixtures: Viekira XRCategories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Doxercalciferol

    go.drugbank.com/drugs/DB06410
    ApprovedInvestigational

    Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients … Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin

  3. Drug

    Streptococcus pneumoniae type 5 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10323
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 5 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 5 of *Streptococcus pneumoniae*.

    Mixtures: PNEUMOVAX 23 Injektionslösung in einer Fertigspritze, PNEUMOVAX 23 Injektionslösung in einer Durchstechflasche
  4. Drug

    Streptococcus pneumoniae type 23f capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10340
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 23f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 23f of *Streptococcus pneumoniae

    Mixtures: PNEUMOVAX 23 Injektionslösung in einer Fertigspritze, PNEUMOVAX 23 Injektionslösung in einer Durchstechflasche
  5. Drug

    NKG2D-ACE2 CAR-NK Cell

    go.drugbank.com/drugs/DB15727
    Investigational

    The IL-15 superagonist increases the activity of NK cells and improves their target cytotoxicity. The GM-CSF acts as a neutralizer for the CAR-T cell-mediated cytokine release and neurotoxicity. … The transmembrane NKG2D and intracellular 2B4 domains are required for optimal NK signalling and subsequent cell-mediated cytotoxicity.

    Synonyms: ACE2 CAR-NK Cell, NKG2D CAR-NK Cell
  6. Drug

    Nitrous acid

    go.drugbank.com/drugs/DB09112
    ApprovedInvestigational

    There is also research to investigate its applicability towards treatments for heart attacks, brain aneurysms, pulmonary hypertension in infants, and Pseudomonas aeruginosa infections. … It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Viltolarsen

    go.drugbank.com/drugs/DB15005
    ApprovedInvestigational

    for exon 53 skipping. … [A218186] Hence, viltolarsen is similar to another PMO, [eteplirsen], which gained FDA approval on September 19, 2016; however, [eteplirsen] is specific for exon 51 skipping while viltolarsen is specific

  8. Drug

    Linvoseltamab

    go.drugbank.com/drugs/DB17447
    ApprovedInvestigational

    FDA in July 2025 for patients who have undergone four or more prior lines. Continued approval in the U.S. is contingent upon verification of clinical benefit in a confirmatory trial. [L53363] … [L53353] It received conditional marketing authorization in the European Union in April 2025 for patients with three or more prior lines of therapy, [L53358] and was granted accelerated approval by the

    Synonyms: human IgG4-based anti-CD3 x anti-BCMA bispecific monoclonal antibody that binds to CD3 and BCMA
  9. Drug

    Betibeglogene autotemcel

    go.drugbank.com/drugs/DB16900
    ApprovedInvestigational

    [A251770,A251785] Betibeglogene autotemcel was approved by the FDA in August 2022 and is the first ex-vivo lentiviral vector gene therapy available in the U.S. for the treatment of people with β-thalassemia … The use of betibeglogene autotemcel is more effective in patients with β-thalassemia with residual β-globin synthesis (non-β<sup>0</sup>/β<sup>0</sup> genotype) compared to those with no detectable β-globin

  10. Drug

    Influenza A virus A/Brisbane/02/2018 IVR-190 (H1N1) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB15515
    Approved

    Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus … Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3.

    Mixtures: Influvac Tetra, suspension for injection in pre-filled syringe, INFLUVAC TETRA, SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE 0.5 ML